Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Balance at beginning of period (in shares) at Dec. 31, 2021		73,709,056
Balance at beginning of period at Dec. 31, 2021	$ 121,741	$ 7	$ 572,213	$ 0	$ (450,479)
Increase (Decrease) in Stockholders' Equity
Issuance of common stock under public offering, net of issuance costs (in shares)		13,169,903
Issuance of common stock under public offering, net of issuance costs	60,462	$ 2	60,460
Exercise of stock options (in shares)		26,951
Exercise of stock options	96		96
Vesting of restricted stock units, net of employee tax obligations (in shares)		167,174
Vesting of restricted stock units	0
Stock-based compensation expense	5,485		5,485
Net (loss) income	(47,258)				(47,258)
Balance at end of period (in shares) at Mar. 31, 2022		87,073,084
Balance at end of period at Mar. 31, 2022	140,526	$ 9	638,254	0	(497,737)
Balance at beginning of period (in shares) at Dec. 31, 2022		105,144,864
Balance at beginning of period at Dec. 31, 2022	92,057	$ 11	746,889	(152)	(654,691)
Increase (Decrease) in Stockholders' Equity
Issuance of common stock under public offering, net of issuance costs (in shares)		3,535,093
Issuance of common stock under public offering, net of issuance costs	$ 21,795		21,795
Exercise of stock options (in shares)	8,826	8,826
Exercise of stock options	$ 34		34
Vesting of restricted stock units, net of employee tax obligations (in shares)		372,291
Vesting of restricted stock units	0
Stock-based compensation expense	6,407		6,407
Other comprehensive gain	164			164
Net (loss) income	(56,163)				(56,163)
Balance at end of period (in shares) at Mar. 31, 2023		109,061,074
Balance at end of period at Mar. 31, 2023	$ 64,294	$ 11	$ 775,125	$ 12	$ (710,854)